Institute of Structural and Molecular Biology, Division of Biosciences, University College London, Gower Street, London WC1E 6BT, United Kingdom.
Laufer Center for Quantitative Biology, Stony Brook University, Nicolls Road, Stony Brook, NY 11790, United States; Department of Chemistry, Stony Brook University, Nicolls Road, Stony Brook, NY 11790, United States.
Biophys Chem. 2024 Apr;307:107168. doi: 10.1016/j.bpc.2023.107168. Epub 2024 Jan 2.
The polypeptide hormone Amylin (also known as islet amyloid polypeptide) plays a role in regulation of glucose metabolism, but forms pancreatic islet amyloid deposits in type 2 diabetes. The process of islet amyloid formation contributes to β-cell dysfunction and the development of the disease. Amylin is produced as a pro-from and undergoes processing prior to secretion. The mature hormone contains an amidated C-terminus. Analysis of an alignment of vertebrate amylin sequences reveals that the processing signal for amidation is strictly conserved. Furthermore, the enzyme responsible for C-terminal amidation is found in all of these organisms. Comparison of the physiologically relevant amidated form to a variant with a free C-terminus (Amylin-COO) shows that replacement of the C-terminal amide with a carboxylate slows, but does not prevent amyloid formation. Pre-fibrillar species produced by both variants are toxic to cultured β-cells, although hAmylin-COO is moderately less so. Amyloid fibrils produced by either peptide are not toxic. Prior work (ACS Pharmacol. Translational. Sci. 1, 132-49 (2018)) shows that Amylin- COO exhibits a 58-fold reduction in activation of the Amylin receptor and 20-fold reduction in activation of the Amylin receptor. Thus, hAmylin-COO exhibits significant toxicity, but significantly reduced activity and offers a reagent for studies which aim to decouple hAmylin's toxic effects from its activity. The different behaviours of free and C-terminal amidated Amylin should be considered when designing systems to produce the polypeptide recombinantly.
多肽激素胰岛淀粉样多肽(也称为胰岛淀粉样多肽)在调节葡萄糖代谢中发挥作用,但在 2 型糖尿病中形成胰腺胰岛淀粉样沉积物。胰岛淀粉样形成的过程导致β细胞功能障碍和疾病的发展。胰岛淀粉样肽以前体形式产生,并在分泌前进行加工。成熟激素含有酰胺化的 C 末端。对脊椎动物胰岛淀粉样肽序列的比对分析表明,酰胺化的加工信号严格保守。此外,所有这些生物体中都发现了负责 C 末端酰胺化的酶。将生理相关的酰胺化形式与具有游离 C 末端的变体(Amylin-COO)进行比较表明,用羧酸盐取代 C 末端酰胺会减缓但不会阻止淀粉样形成。两种变体产生的预纤维物种对培养的β细胞都有毒性,尽管 hAmylin-COO 的毒性略低。由任一肽产生的淀粉样纤维都没有毒性。先前的工作(ACS Pharmacol. Translational. Sci. 1, 132-49 (2018))表明,Amylin-COO 对胰岛淀粉样肽受体的激活作用降低了 58 倍,对胰岛淀粉样肽受体的激活作用降低了 20 倍。因此,hAmylin-COO 表现出显著的毒性,但活性显著降低,并为旨在将 hAmylin 的毒性作用与其活性分离的研究提供了试剂。在设计重组产生多肽的系统时,应考虑游离和 C 末端酰胺化胰岛淀粉样肽的不同行为。